Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20265527 | 0.80 | HSD17B10 (0.46) | MAPTSMN1; SMN2MAPK1ALDH1A1MEN1 | |
| SCHEMBL367990 | 0.80 | MAPT (0.47) | POLBMAPTNPC1SMN1; SMN2MAPK1 | |
| SCHEMBL511979 | 0.78 | HTT (0.49) | MAPTSMN1; SMN2MAPK1ALDH1A1MEN1 | |
| SCHEMBL10153123 | 0.78 | ALDH1A1 (0.49) | POLBMAPTNPC1SMN1; SMN2MAPK1 | |
| SCHEMBL363067 | 0.75 | NPC1 (0.39) | POLBNPC1SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL2625708 | 0.74 | TLR2 (0.47) | POLBMAPTNPC1SMN1; SMN2MAPK1 | |
| SCHEMBL2625709 | 0.74 | MAPT (0.43) | POLBMAPTNPC1SMN1; SMN2MAPK1 | |
| SCHEMBL12306339 | 0.74 | MAPT (0.42) | POLBMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3757819 | 0.73 | MAPT (0.54) | POLBMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL361528 | 0.72 | CYP19A1 (0.53) | MAPTNPC1SMN1; SMN2MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835482-B2 | Substituted indazole and aza-indazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8546440-B2 | Substituted bicyclic imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120095036-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095036-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| US-20110237580-A1 | SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals, Inc. | 2011-09-29 | — | — | US | disclosed |
| WO-2010145883-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010094647-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095036-A1 | NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | POLB 4155/4885MAPT 3521/4885NPC1 876/4885 |
| US-20110237580-A1 | SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | POLB 3235/4885MAPT 371/4885NPC1 884/4885 |
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | POLB 3804/4885MAPT 1724/4885NPC1 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.